Merck Reports Q1 Revenue Growth Amid Acquisition Charges
Merck & Co., Inc. reported first-quarter revenue of $16.3 billion, up 5% year-over-year, driven by oncology sales and new product contributions. However, a GAAP loss was recorded due to an acquisition charge from Sedera. The company raised non-GAAP guidance for the full year.
Tickers: $MRK
Topics: acquisition animal health guidance update oncology pharmaceuticals